455 E. MEDICAL CENTER BLVD, HOUSTON, TX
Appoints Leigh Steinberg to Board of Directors
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Appoints Kathleen 'Kate' Rubins, Ph.D. to Board of Directors
Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
FibroBiologics, Inc. Approves 2026 Equity and Incentive Compensation Plan
FibroBiologics Enters At The Market Offering Agreement with H.C. Wainwright
Stock Options Granted to Executives at FibroBiologics, Inc.
Annual Report to Security Holders
Q2
Amended Annual Report
FY 2024
Q3
Q1
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(4)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement